{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-in-pregnancy/prescribing-information/methyldopa/","result":{"pageContext":{"chapter":{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa","depth":2,"htmlHeader":"<!-- begin field 2911f192-5067-4003-940f-7abc71f37bff --><h2>Methyldopa</h2><!-- end field 2911f192-5067-4003-940f-7abc71f37bff -->","summary":"","htmlStringContent":"<!-- begin item 42bd349d-ce28-4deb-ae02-0edfd839d058 --><!-- end item 42bd349d-ce28-4deb-ae02-0edfd839d058 -->","topic":{"id":"6ecaddc4-ff30-5cf4-ad9e-1df6efa32f1b","topicId":"b42a4357-926e-40db-93be-eb2734585661","topicName":"Hypertension in pregnancy","slug":"hypertension-in-pregnancy","lastRevised":"Last revised in July 2020","chapters":[{"id":"be1a3062-ba16-5320-bc1f-7931438b3b5e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"37d79826-12c0-54a5-859c-f5aab239dccb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"000e1ae9-fec8-5c7e-93fa-aac37cbed3b1","slug":"changes","fullItemName":"Changes"},{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update"}]},{"id":"a142cb05-c8c8-5f0b-a31f-aee4193f794a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fb45ed4d-238b-5c83-a4c9-503c743ce614","slug":"goals","fullItemName":"Goals"},{"id":"9fe5bf45-a5b8-5910-9d8c-6c7d392f1779","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"152c0aed-a09e-585e-be86-456cff579be0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e424db7c-6f59-5395-8125-3f64c8335e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"388966c0-e5d0-5421-b48f-b9c11780841e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"aa780aa5-6dd7-53a0-893d-5f60840b81a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition"},{"id":"a31e2e01-f95d-55d6-a81d-9f251edbf121","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe25ef6b-b112-589a-aa03-6f59c10bb254","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1cacb2e-13ff-5c3f-9767-77524f5938ad","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5a7a190a-9065-5e86-a995-19f480ddc1ae","slug":"complications","fullItemName":"Complications"},{"id":"39c857d6-2892-50eb-926a-0e42813dfdc8","slug":"long-term-health-implications","fullItemName":"Long-term health implications"}]},{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"29858bb6-e45a-5a43-bcf6-707da3b7f93e","slug":"pre-eclampsia","fullItemName":"Scenario: Pre-eclampsia"},{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks"},{"id":"525f57d9-c730-5acb-bc09-7a9500642f44","slug":"new-hypertension-after-20-weeks","fullItemName":"Scenario: New hypertension after 20 weeks"},{"id":"4fae554e-dd42-5116-9621-ba14519b2cc7","slug":"proteinuria-no-hypertension-after-20-weeks","fullItemName":"Scenario: Proteinuria and no hypertension after 20 weeks"},{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up"}]},{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d81aa3f7-0ac1-557e-aeb4-85c389e3d449","slug":"aspirin","fullItemName":"Aspirin"},{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol"},{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa"},{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"be2fc921-a370-593b-83f0-3adf0dbcb226","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4e8e53ad-14b2-51b1-b527-d41b79469ddf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"766ae496-9560-5803-92fa-8d7f71dc073e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0306f0ee-51ab-53f0-bfba-47ceda06c33c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"204ea692-4044-51c2-b0d6-84f596e7ff27","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fe018251-2fcc-5a91-9662-fd930649403a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"961ee437-62d3-5138-83b6-d59d61ff6085","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a96b6bfe-8e8a-51bd-beb4-c719aab1df08","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"4d1d8507-3c98-53c1-a2d8-12146e69ab5f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b464b8fb-6c69-494c-b5d3-327f952ff20c --><h3>Contraindications and cautions</h3><!-- end field b464b8fb-6c69-494c-b5d3-327f952ff20c -->","summary":"","htmlStringContent":"<!-- begin item bda73047-fdd3-40c8-9780-aaa0c4fc27cd --><!-- begin field bfb3534a-f209-4da7-bcc0-bb031c1ffe98 --><ul><li>Methyldopa is not specifically licensed for the treatment of hypertension in pregnancy. However, the manufacturer states that methyldopa can be used during pregnancy if there is no safer alternative available.</li></ul><p><strong>Methyldopa should not be prescribed to people with:</strong></p><ul><li>Active hepatic disease, such as acute hepatitis and active cirrhosis.</li><li>Depression.</li><li>Phaeochromocytoma.</li><li>Acute porphyria.</li></ul><p><strong>Methyldopa should be used with caution in people with:</strong></p><ul><li>History of hepatic disease or renal impairment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field bfb3534a-f209-4da7-bcc0-bb031c1ffe98 --><!-- end item bda73047-fdd3-40c8-9780-aaa0c4fc27cd -->","subChapters":[]},{"id":"7bda1131-acd6-5505-a030-c0976fa7ff17","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 0e2c1cd6-90f3-4145-84df-1661f9cd1ab1 --><h3>Adverse effects</h3><!-- end field 0e2c1cd6-90f3-4145-84df-1661f9cd1ab1 -->","summary":"","htmlStringContent":"<!-- begin item 0c021c58-c633-4c66-9c11-5da6672622c0 --><!-- begin field ae6b52de-1a24-4d31-8879-70afcc55d2ce --><p><strong>Adverse effects of methyldopa include:</strong></p><ul><li>Cardiac — bradycardia, aggravation of angina pectoris, myocarditis, pericarditis.</li><li>Haematological — haemolytic anaemia, bone marrow depression, leucopenia, granulocytopenia, thrombocytopenia, eosinophilia.</li><li>Neurological — sedation (usually transient), headache, paraesthesia, Parkinsonism, Bell's palsy, involuntary choreoathetotic movements, impaired mental acuity, dizziness, light headedness, symptoms of cerebrovascular insufficiency, asthenia or weakness.</li><li>Gastrointestinal — gastrointestinal disorders, dry mouth, sore or 'black' tongue, pancreatitis, hepatitis, jaundice.</li><li>Skin — rashes (including toxic epidermal necrolysis), lupus-like syndrome, angioedema, urticaria. </li><li>Neuropsychiatric — nightmares, reversible mild psychoses, depression.</li><li>Endocrine — hyperprolactinaemia, gynaecomastia, amenorrhoea, lactation. </li><li>Other — prolonged carotid sinus hypersensitivity, nasal stuffiness, arthralgia, myalgia, sialadenitis, orthostatic hypotension, oedema (and weight gain), fever, decreased libido.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field ae6b52de-1a24-4d31-8879-70afcc55d2ce --><!-- end item 0c021c58-c633-4c66-9c11-5da6672622c0 -->","subChapters":[]},{"id":"6e9cba70-baa8-5558-95a5-4b33c67c1e3e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b716dbf3-94f4-481f-acfa-227fd8e380b2 --><h3>Drug interactions</h3><!-- end field b716dbf3-94f4-481f-acfa-227fd8e380b2 -->","summary":"","htmlStringContent":"<!-- begin item 9e877c3d-680b-48ee-a265-1913bcfe4863 --><!-- begin field bcde4d2b-6be6-425e-94e0-03924dac5b42 --><p><strong>Combinations requiring caution include:</strong></p><ul><li>Lithium — when methyldopa and lithium are given concomitantly the person should be monitored carefully for symptoms of lithium toxicity such as diarrhoea, abdominal pains, nausea, vomiting, dizziness, weakness, tremor, ataxia, and slurred speech.<ul><li>If lithium toxicity is suspected, do an urgent lithium level and seek specialist advice.</li></ul></li><li>Other antihypertensives — potentiation of antihypertensive action may occur.</li><li>Sympathomimetics (for example dopamine), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants — may reduce the antihypertensive effect of methyldopa.</li><li>Phenothiazines — may have additive hypotensive effects but can also reduce the antihypertensive effect of methyldopa.</li><li>Iron — may decrease the bioavailability of methyldopa reducing its effect on blood pressure control.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field bcde4d2b-6be6-425e-94e0-03924dac5b42 --><!-- end item 9e877c3d-680b-48ee-a265-1913bcfe4863 -->","subChapters":[]},{"id":"3364de93-eef9-56bc-aa62-ef66e7465e0f","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field 19405d3a-3d9f-4abf-b6d4-45c330c68ce6 --><h3>Dosing information</h3><!-- end field 19405d3a-3d9f-4abf-b6d4-45c330c68ce6 -->","summary":"","htmlStringContent":"<!-- begin item 188a632a-4ae9-49ff-8fd7-7b77a5902574 --><!-- begin field 55d8ceaf-d842-41eb-b2ab-c2f0e5655c8b --><ul><li>Start with a dose of 250 mg 2–3 times a day.</li><li>If required and tolerated, increase the dose gradually at intervals of at least 2 days.</li><li>Maximum dose is 3 g daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 55d8ceaf-d842-41eb-b2ab-c2f0e5655c8b --><!-- end item 188a632a-4ae9-49ff-8fd7-7b77a5902574 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}